{"id":"gemcitabine-with-r115777","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL3039516","moleculeType":"Small molecule","molecularWeight":"527.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine acts as a deoxycytidine analog that is incorporated into DNA, causing chain termination and inhibiting ribonucleotide reductase to deplete deoxyribonucleotides. R115777 inhibits farnesyltransferase, preventing the post-translational modification and membrane localization of Ras proteins, which are frequently mutated in pancreatic and other cancers. The combination targets both DNA synthesis and oncogenic signaling pathways.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while R115777 is a farnesyltransferase inhibitor that blocks Ras protein activation, together targeting cancer cell proliferation through complementary pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:52.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer"},{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT00026104","phase":"PHASE2","title":"Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-11","conditions":"Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer","enrollment":154},{"nctId":"NCT00100750","phase":"PHASE1, PHASE2","title":"Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09","conditions":"Recurrent Breast Carcinoma, Stage IV Breast Cancer","enrollment":31},{"nctId":"NCT00055757","phase":"PHASE2","title":"Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10","conditions":"Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT00003707","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"1998-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":22},{"nctId":"NCT00005648","phase":"PHASE3","title":"Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1999-11","conditions":"Pancreatic Neoplasms","enrollment":688}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine with R115777","genericName":"Gemcitabine with R115777","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while R115777 is a farnesyltransferase inhibitor that blocks Ras protein activation, together targeting cancer cell proliferation through complementary pathways. Used for Pancreatic cancer, Advanced solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}